Fig. 4: T cell exhaustion score and soluble PD-L1 and IFNy follow the immune evolution during metastatic progression.
From: Converging and evolving immuno-genomic routes toward immune escape in breast cancer
a Barplot showing quantification of T cell exhaustion metagene. The T cell exhaustion metagene score was applied to the specimens of the TNBC index patient (M1-day 799 chest wall metastasis, obtained before treatment with an immune checkpoint inhibitor atezolizumab, and 17 parallel multiregion metastases) and the cohort of 10 TNBC patients (10 primary tumors and 42 multiregion metastases) that have RNA-seq gene expression available. Source data are provided as a Source Data file. b Longitudinal monitoring of soluble PD-L1 and IFNy as liquid biopsies (proteomic level) and in tissue (gene expression scores). Clinical responses are depicted. Source data are provided as a Source Data file. aPD-L1 anti-programmed death-ligand 1 monoclonal antibody, aPD-1 anti-programmed cell death protein 1 monoclonal antibody, CR complete response, d day, PR partial response, PD progressive disease, Rec recurrence, SD stable disease, TLR7 Toll-like receptor 7.
